Winton Group’s Bionano Genomics BNGO Stock Holding History

Winton Group’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-818	Closed	-$2.7M	–	1047
2021 Q3	$2.7M	Buy	818 +160	+24%	+$560K	0.15%	115
2021 Q2	$2.89M	Buy	+658	New	+$2.6M	0.16%	83

Other funds holding BNGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mitsubishi UFJ Asset Management Tokyo, Japan $149B AUM 24.71% 1-Year Est. Return

Winton Group's BNGO Position: Q4 2021 in Review

Winton Group sold out of Bionano Genomics (BNGO) in Q4 2021, closing a stake of 818 shares — an estimated $2.7M sold.

Winton Group first reported a position in BNGO in Q2 2021 and held it in 2 quarters. The position peaked at $2.89M in Q2 2021. 149 funds tracked by Wall St. Rank hold BNGO as of Q4 2021.

Winton Group reported no remaining Bionano Genomics position as of Q4 2021 after selling out during the quarter.
Winton Group sold 818 Bionano Genomics shares in Q4 2021, an estimated $2.7M.
Winton Group first reported a position in Bionano Genomics in Q2 2021 and held it in 2 quarters.
Winton Group's Bionano Genomics position peaked at $2.89M in Q2 2021.
149 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2021.

Based on Winton Group's 13F filing for Q4 2021, filed 10 Feb 2022.